Oncocytic carcinoma of the breast: Frequency, morphology and follow-up

Department of Haematology and Oncological Sciences L. and A. Seragnoli, Section of Anatomic Pathology at Bellaria Hospital, University of Bologna, 40139 Bologna, Italy.
Human pathology (Impact Factor: 2.77). 02/2011; 42(2):166-75. DOI: 10.1016/j.humpath.2010.07.014
Source: PubMed


Oncocytic breast carcinomas are tumors composed of no fewer than 70% of oncocytic cells (World Health Organization). The purpose of this study was to determine the frequency, morphologic, immunohistochemical, and clinical features of invasive oncocytic carcinoma in a large series. Twenty-eight cases of putative oncocytic breast carcinoma (selected cases group) and 76 consecutive cases of invasive breast carcinoma (consecutive cases group) were analyzed. Immunohistochemistry for mitochondria, gross cystic disease fluid protein 15, chromogranin, estrogen receptor, progesterone receptor, androgen receptor, HER2/Neu, cytokeratin 7, cytokeratin 14, epithelial membrane antigen, and differentiation cluster 68 was performed. Score for mitochondria was based on intensity and percentage of immunopositive cells. Classes were as follows: (1) oncocytic carcinoma: at least 70%, 3+; (2) mitochondrion-rich carcinoma: 50% to 70%, 3+, or more than 50%, 2+; and (3) all the other cases were referred to as invasive breast carcinoma. Ultrastructural examination was available for 6 cases of oncocytic carcinoma. Morphologic and immunohistochemical features of the 3 groups were compared using Fisher exact test (P < .05). For overall survival analysis, Kaplan-Maier curves were compared using log-rank and Wilcoxon tests (P < .05). Our results suggest that oncocytic breast carcinoma is a morphologic entity with distinctive histologic and ultrastructural features. Mitochondrion-rich carcinomas are histologically similar to oncocytic carcinomas and constitute 19.7% of all invasive carcinomas, indicating that cytoplasmic eosinophilia in breast cancer cells is often due to accumulation of mitochondria. Oncocytic carcinomas and mitochondrion-rich carcinomas are more often grade III tumors and show human epidermal growth factor receptor 2 overexpression. Clinical features and overall survival of oncocytic carcinomas are not distinctive because they are similar to those of the other cases when matched for grade and stage.

Download full-text


Available from: Moira Ragazzi, Aug 06, 2014
  • Source
    • "Moreover, positive immunohistochemical staining for a mitochondrial antigen (monoclonal, 113-1, diluted 1:75, Biogenex, Fremont, California 94538, USA) confirmed the morphological interpretation . Immunostained cytoplasm for mitochondrion antibody was scored using the semiquantitative scale reported by Ragazzi et al [20] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Histological and cytological criteria in predicting clinical outcomes in patients with oncocytic poorly differentiated carcinoma (PDC) of the thyroid were investigated. In a set of 102 PDC patients, we performed a computer-assisted evaluation of cell size based on two different methods. Univariate analysis showed that cell size was a discriminant prognostic parameter in oncocytic PDC (30 cases) but not in the non-oncocytic carcinomas cases (72 cases). Patients with oncocytic PDC with small medium cell size had a significantly increased risk of death (p=0.029) and a decrease of disease-free survival (p=0.014). This correlation was absented in cases of non-oncocytic PTC, where age and extensive vascular invasion were significant indicators of progression. The proposed morphological signature shows a robust discriminatory ability when tested on the oncocytic PDC group and cell size assessment could thus be proposed as an inexpensive and readily evaluable parameter for predicting prognosis and planning therapy in this tumor type.
    Human pathology 07/2014; 45(7). DOI:10.1016/j.humpath.2014.02.027 · 2.77 Impact Factor
  • Source
    • "The antibody MTC02 (mouse monoclonal to mitochondria) recognizes a 60 kDa non glycosylated protein component of mitochondria found in human cells, and has been used to determine the mitochondrial content of tumor cells in a variety of previous studies. For example, earlier studies used MTC02 to determine the molecular genetic alterations [13] and the frequency, morphology and clinical features of mitochondrion-rich breast cancers [26]. A tissue microarray (TMA) containing 11,152 prostate cancer specimens with clinical follow-up information and an attached molecular database was analyzed in order to evaluate the clinical significance of mitochondria content, and to search for possible associations with molecularly defined cancer subgroups. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondria are suggested to be important organelles for cancer initiation and promotion. This study was designed to evaluate the prognostic value of MTC02, a marker for mitochondrial content, in prostate cancer. Immunohistochemistry of using an antibody against MTC02 was performed on a tissue microarray (TMA) containing 11,152 prostate cancer specimens. Results were compared to histological phenotype, biochemical recurrence, ERG status and other genomic deletions by using our TMA attached molecular information. Tumor cells showed stronger MTC02 expression than normal prostate epithelium. MTC02 immunostaining was found in 96.5% of 8,412 analyzable prostate cancers, including 15.4% tumors with weak, 34.6% with moderate, and 46.5% with strong expression. MTC02 expression was associated with advanced pathological tumor stage, high Gleason score, nodal metastases (p < 0.0001 each), positive surgical margins (p = 0.0005), and early PSA recurrence (p < 0.0001) if all cancers were jointly analyzed. Tumors harboring ERG fusion showed higher expression levels than those without (p < 0.0001). In ERG negative prostate cancers, strong MTC02 immunostaining was linked to deletions of PTEN, 6q15, 5q21, and early biochemical recurrence (p < 0.0001 each). Moreover, multiple scenarios of multivariate analyses suggested an independent association of MTC02 with prognosis in preoperative settings. Our study demonstrates high-level MTC02 expression in ERG negative prostate cancers harboring deletions of PTEN, 6q15, and 5q21. Additionally, increased MTC02 expression is a strong predictor of poor clinical outcome in ERG negative cancers, highlighting a potentially important role of elevated mitochondrial content for prostate cancer cell biology.
    Molecular Cancer 11/2013; 12(1):145. DOI:10.1186/1476-4598-12-145 · 4.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is uncommon in males. Approximately 85 % of male mammary carcinomas are of the infiltrating duct type. One of the uncommon subtypes is oncocytic carcinoma (OC). Oncocytic tumors may occur in several different anatomical sites such as meninges, choroid plexus, soft tissue, and gastrointestinal tract; they tend to affect more frequently the endocrine and glandular epithelia such as salivary gland and renal tubules that have high metabolic activity. At present, OC is a morphological entity, and there is no practical reason for including OC into everyday reports, since any significant clinical features are found. However, more cases of OC of the breast have to be studied in view of the fact that oncocytic tumors of colon, thyroid, and meninges seem to be resistant to radiation therapy, a finding that might be taken into consideration when planning the treatment in breast carcinomas.
    Indian Journal of Surgery 06/2013; 75(1). DOI:10.1007/s12262-012-0635-0 · 0.26 Impact Factor
Show more